Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

John Thomas Potts Jr., M.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. M01RR001066 (SLAVIN, PETER L) Dec 1, 1997 - Nov 30, 2007
    General Clinical Research Center
    Role: Co-Principal Investigator
  2. P01DK011794 (POTTS, JOHN T) Aug 1, 1997 - Nov 30, 2018
    Hormonal Control of Calcium Metabolism
    Role: Principal Investigator
  3. R13AR044475 (POTTS, JOHN T) Jan 1, 1997 - Dec 31, 1997
    Role: Principal Investigator
  4. K12DK001410 (POTTS, JOHN T) Jul 1, 1985 - Jun 30, 1998
    Role: Principal Investigator
  5. K12AM001410 (POTTS, JOHN T) Jul 1, 1985 - Jun 30, 1990
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Noda H, Okazaki M, Joyashiki E, Tamura T, Kawabe Y, Khatri A, Jueppner H, Potts JT, Gardella TJ, Shimizu M. Optimization of PTH/PTHrP Hybrid Peptides to Derive a Long-Acting PTH Analog (LA-PTH). JBMR Plus. 2020 Jul; 4(7):e10367. PMID: 32666018.
  2. Noda H, Guo J, Khatri A, Dean T, Reyes M, Armanini M, Brooks DJ, Martins JS, Schipani E, Bouxsein ML, Demay MB, Potts JT, Jüppner H, Gardella TJ. An Inverse Agonist Ligand of the PTH Receptor Partially Rescues Skeletal Defects in a Mouse Model of Jansen's Metaphyseal Chondrodysplasia. J Bone Miner Res. 2020 Mar; 35(3):540-549. PMID: 31693237.
  3. Martin TJ, Clemens TL, Compston JE, Potts JT, Thakker RV. Jeffrey Lima Hayes O'Riordan: March 27, 1931 - October 9, 2017. J Bone Miner Res. 2018 Jan; 33(1):1-2. PMID: 29194768.
    Citations:    Fields:    
  4. Guo J, Khatri A, Maeda A, Potts JT, Jüppner H, Gardella TJ. Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment. J Bone Miner Res. 2017 01; 32(1):86-98. PMID: 27428040.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  5. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT, Brandi ML, Bilezikian JP. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017 01; 28(1):1-19. PMID: 27613721.
    Citations: 23     Fields:    Translation:Humans
  6. Shimizu M, Joyashiki E, Noda H, Watanabe T, Okazaki M, Nagayasu M, Adachi K, Tamura T, Potts JT, Gardella TJ, Kawabe Y. Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys. J Bone Miner Res. 2016 07; 31(7):1405-12. PMID: 26865415.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  7. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT. Management of Hypoparathyroidism: Summary Statement and Guidelines. J Clin Endocrinol Metab. 2016 Jun; 101(6):2273-83. PMID: 26943719.
    Citations: 11     Fields:    Translation:Humans
  8. Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT. Management of Hypoparathyroidism: Present and Future. J Clin Endocrinol Metab. 2016 Jun; 101(6):2313-24. PMID: 26938200.
    Citations: 5     Fields:    Translation:Humans
  9. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014 Oct; 99(10):3561-9. PMID: 25162665.
    Citations: 91     Fields:    Translation:Humans
  10. Potts JT. A conversation with John T. Potts Jr. Interview by Ushma S. Neill. J Clin Invest. 2013 Nov; 123(11):4544-5. PMID: 24177463.
    Citations:    Fields:    Translation:HumansAnimals
  11. Potts JT. Acceptance remarks. J Clin Invest. 2013 Nov; 123(11):4977-8. PMID: 24177470.
    Citations:    Fields:    Translation:Humans
  12. Maeda A, Okazaki M, Baron DM, Dean T, Khatri A, Mahon M, Segawa H, Abou-Samra AB, Jüppner H, Bloch KD, Potts JT, Gardella TJ. Critical role of parathyroid hormone (PTH) receptor-1 phosphorylation in regulating acute responses to PTH. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):5864-9. PMID: 23533279.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  13. Khan AA, Brandi ML, Potts JT, Bilezikian JP. Supplement on primary hyperparathyroidism. J Clin Densitom. 2013 Jan-Mar; 16(1):3. PMID: 23294731.
    Citations:    Fields:    Translation:Humans
  14. Potts JT. A short history of parathyroid hormone, its biological role, and pathophysiology of hormone excess. J Clin Densitom. 2013 Jan-Mar; 16(1):4-7. PMID: 23374734.
    Citations: 1     Fields:    Translation:Humans
  15. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012 Jul; 97(7):2272-82. PMID: 22523337.
    Citations: 43     Fields:    Translation:Humans
  16. Lewiecki EM, Bilezikian JP, Jankowski LG, McCloskey EV, Miller PD, Morgan SL, Orwoll ES, Potts JT. Proceedings of the 2011 Santa Fe Bone symposium. J Clin Densitom. 2012 Jan-Mar; 15(1):1-20. PMID: 22284629.
    Citations:    Fields:    Translation:Humans
  17. Bilezikian JP, Khan A, Potts JT, Brandi ML, Clarke BL, Shoback D, Jüppner H, D'Amour P, Fox J, Rejnmark L, Mosekilde L, Rubin MR, Dempster D, Gafni R, Collins MT, Sliney J, Sanders J. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011 Oct; 26(10):2317-37. PMID: 21812031.
    Citations: 58     Fields:    Translation:Humans
  18. Nagai S, Okazaki M, Segawa H, Bergwitz C, Dean T, Potts JT, Mahon MJ, Gardella TJ, Jüppner H. Acute down-regulation of sodium-dependent phosphate transporter NPT2a involves predominantly the cAMP/PKA pathway as revealed by signaling-selective parathyroid hormone analogs. J Biol Chem. 2011 Jan 14; 286(2):1618-26. PMID: 21047792.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  19. Potts JT. The early days at the National Institutes of Health. Ann N Y Acad Sci. 2010 Mar; 1192:1-4. PMID: 20392210.
    Citations:    Fields:    Translation:Humans
  20. Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, Gardella TJ, Vilardaga JP. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol. 2009 Oct; 5(10):734-42. PMID: 19701185.
    Citations: 134     Fields:    Translation:HumansAnimalsCells
  21. Khan AA, Bilezikian JP, Potts JT. Asymptomatic primary hyperparathyroidism: a commentary on the revised guidelines. Endocr Pract. 2009 Jul-Aug; 15(5):494-8. PMID: 19546049.
    Citations: 3     Fields:    Translation:Humans
  22. Khan AA, Bilezikian JP, Potts JT. The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab. 2009 Feb; 94(2):333-4. PMID: 19193907.
    Citations: 18     Fields:    Translation:Humans
  23. Bilezikian JP, Khan AA, Potts JT. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009 Feb; 94(2):335-9. PMID: 19193908.
    Citations: 156     Fields:    Translation:Humans
  24. Okazaki M, Ferrandon S, Vilardaga JP, Bouxsein ML, Potts JT, Gardella TJ. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci U S A. 2008 Oct 28; 105(43):16525-30. PMID: 18946036.
    Citations: 39     Fields:    Translation:HumansAnimalsCells
  25. Potts JT, Gardella TJ. Progress, paradox, and potential: parathyroid hormone research over five decades. Ann N Y Acad Sci. 2007 Nov; 1117:196-208. PMID: 18056044.
    Citations: 28     Fields:    Translation:HumansAnimalsCells
  26. Dean T, Vilardaga JP, Potts JT, Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008 Jan; 22(1):156-66. PMID: 17872377.
    Citations: 44     Fields:    Translation:HumansAnimalsCells
  27. Dean T, Linglart A, Mahon MJ, Bastepe M, Jüppner H, Potts JT, Gardella TJ. Mechanisms of ligand binding to the parathyroid hormone (PTH)/PTH-related protein receptor: selectivity of a modified PTH(1-15) radioligand for GalphaS-coupled receptor conformations. Mol Endocrinol. 2006 Apr; 20(4):931-43. PMID: 16339275.
    Citations: 25